Breaking News, Collaborations & Alliances

AGC Biologics Enters Gene Therapy Manufacturing Agreement with AAVantgarde

AGC Biologics to provide GMP manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics has entered a new manufacturing agreement with AAVantgarde, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies: AAVB-039 for Stargardt disease: This therapy addresses the most common inherited form of macular degen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters